A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the lntraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Rectum or Pancreas
Latest Information Update: 17 Feb 2019
At a glance
- Drugs SGM 101 (Primary)
- Indications Pancreatic cancer; Rectal cancer
- Focus Adverse reactions
Most Recent Events
- 12 May 2016 New trial record